Table 2 Postinfusion progress of... | American Society of Hematology

Table 2

Postinfusion progress of patients receiving CMV-specific T cells

Patient no.	Day of infusion	Dose,10⁷/m²	Infusional adverse events, Y/N	Last day of follow-up	CMV reactivation*			GVHD†			Non-CMV infection‡Y/N	Relapse		Other§Y/N
Patient no.	Day of infusion	Dose,10⁷/m²	Infusional adverse events, Y/N	Last day of follow-up	Y/N	Day	Treatment	Y/N	Day	Grade	Non-CMV infection‡Y/N	Y/N	Day	Other§Y/N
06213	45	2	N	419	Y	46 146	Nil	Y	90, 201	III	N	N		N
0702	31	2	N	239	Y	38	Val	N			N	N		Y
06205	101	2	N	453	N			Y	220	II	Y	N		N
0735	38	2	N	359	N			N			N	Y	174	Y
0743	38	2	N	335	Y	45	Nil	Y	171	II	N	N		Y
0775	59	2	N	311	N			N			N	Y	166	N
0786	61	2	N	288	N			N			N	N		N
07110	68	2	N	239	N			N			N	N		N
07141	50	2	N	201	N			N			N	N		N
07143	45	2	N	214	Y	50 101	Val	Y	87	II	Y	N		N
07138	73	2	N	213	N			N			N	Y	137	N
07169	61	2	N	155	N			N			N	N		N

Patient no.	Day of infusion	Dose,10⁷/m²	Infusional adverse events, Y/N	Last day of follow-up	CMV reactivation*			GVHD†			Non-CMV infection‡Y/N	Relapse		Other§Y/N
Patient no.	Day of infusion	Dose,10⁷/m²	Infusional adverse events, Y/N	Last day of follow-up	Y/N	Day	Treatment	Y/N	Day	Grade	Non-CMV infection‡Y/N	Y/N	Day	Other§Y/N
06213	45	2	N	419	Y	46 146	Nil	Y	90, 201	III	N	N		N
0702	31	2	N	239	Y	38	Val	N			N	N		Y
06205	101	2	N	453	N			Y	220	II	Y	N		N
0735	38	2	N	359	N			N			N	Y	174	Y
0743	38	2	N	335	Y	45	Nil	Y	171	II	N	N		Y
0775	59	2	N	311	N			N			N	Y	166	N
0786	61	2	N	288	N			N			N	N		N
07110	68	2	N	239	N			N			N	N		N
07141	50	2	N	201	N			N			N	N		N
07143	45	2	N	214	Y	50 101	Val	Y	87	II	Y	N		N
07138	73	2	N	213	N			N			N	Y	137	N
07169	61	2	N	155	N			N			N	N		N

Day indicates day after HSCT; and Val, valciclovir.

Any positive peripheral blood CMV PCR.

†

Episodes of acute GVHD after T-cell infusion.

‡

Infectious events not associated with any evidence of CMV reactivation.

Includes bone marrow failure day 125 in patient 0702, likely secondary to trimethoprim/sulphamethoxazole, necessitating a second transplantation with death from uncontrolled GVHD on day 239, death from relapse in patient 0735 on day 359, and an episode of hypoxia with uncertain etiology in patient 0743 on day 281.

View Large

This Feature Is Available To Subscribers Only